Se hai scelto di non accettare i cookie di profilazione e tracciamento, puoi aderire all’abbonamento "Consentless" a un costo molto accessibile, oppure scegliere un altro abbonamento per accedere ad ANSA.it.
Ti invitiamo a leggere le Condizioni Generali di Servizio, la Cookie Policy e l'Informativa Privacy.
In evidenza
Extra
Comunicato stampa
Comunicato stampa
Responsabilità editoriale di Business Wire
Comunicato stampa - Responsabilità editoriale di Business Wire
Brenus Pharma unveils groundbreaking results during the American Association Cancer Research (AACR) Annual meeting 2024 – San Diego (April 5-10).
“Efficacy of the STC-1010 1 a new allogeneic cancer vaccine in different colorectal cancer models” | Abstract 5003 https://doi.org/10.1158/1538-7445.AM2024-5003
This communication confirms the ability of Brenus’ next gen immunotherapy, STC-1010, to fight against resistant colorectal tumors with excellent tolerability.
Additionally, multi-omics analysis of STC-1010 batches confirmed consistent quality and batch-to-batch reproducibility, through standardized and scalable production.
STC-1010 was tested in several models extrapolating human conditions (ex-vivo; in-ovo,) using PBMCs from different donors. Results showed a significant immune response activation coupled with a massive and robust tumor killing that has been consistent with our 3 latest STC1010 batches manufactured. Metastasis reduction has also been shown with in-ovo model.
Results show the potential of STC-1010 in clinical settings to treat patients with colorectal cancer causing 9.7 million death per year.
https://www.brenus-pharma.com/ | Follow us on LinkedIn
1
STC-1010 is a next-generation cancer immunotherapy produced by Allogeneic STC's proprietary Brenus platform. It’s specifically designed to combat colorectal cancer including MSS and MSI-H populations in its first line of treatment for the first indication. STC Platform mimics relapse conditions and allows eduction of patient’s immune system against resistant tumor.
2
Brenus Pharma, Lyon, France,
3
INSERM U1194 IRCM, Montpellier, France,
4
CNRS 6302, Dijon, France,
5
Anaquant, Lyon, France
6
Inovotion, La Tronche, France,
7
Explicyte, Bordeaux, France
8
Inserm 1231 CGFL, Dijon, France
View source version on businesswire.com: https://www.businesswire.com/news/home/20240409632375/en/
mbrun@brenus-pharma.com | (+33) 787768772
Permalink: http://www.businesswire.com/news/home/20240409632375/en
Comunicato stampa - Responsabilità editoriale di Business Wire
Ultima ora